Does Health Net Cover Eliquis?

How Health Net Formulary Tiers Affect Eliquis Coverage

Health Net organizes prescription drugs into tiers that determine out-of-pocket costs. Eliquis lands on Tier 3 or Tier 4 in most commercial and exchange-based plans, which places it in the brand-name drug category rather than the lower-cost generic tiers. The specific tier depends on which Health Net product a member holds (HMO, PPO, EPO, or Medicare Advantage).

Tier 1 covers generics and costs the least, often $5 to $15 per fill. Tier 2 includes preferred brands. Tier 3 and Tier 4 carry progressively higher cost-sharing. Because apixaban remains patent-protected with no FDA-approved generic equivalent available as of 2026, Health Net cannot place it on a generic tier 1. Members on high-deductible plans may pay the full retail price (roughly $600 to $700 monthly) until their deductible is met.

Health Net publishes formulary documents for each plan year. These are accessible through the member portal or by calling the number on the back of the insurance card. Formularies can change at the start of each plan year or, in some cases, mid-year with proper notice. A drug listed in 2025 may shift tiers in 2026, so confirming current placement before filling a prescription matters. The American Heart Association notes that medication cost is one of the leading drivers of nonadherence in patients prescribed oral anticoagulants for atrial fibrillation 2.

Health Net Medicare Advantage and Part D Coverage for Eliquis

Medicare Advantage plans offered by Health Net follow Centers for Medicare & Medicaid Services (CMS) formulary guidelines, which require coverage of at least two drugs in each therapeutic class. Direct oral anticoagulants (DOACs) fall under the anticoagulant class, and CMS mandates that Part D plans cover "all or substantially all" anticoagulants 3. This means Eliquis is almost always covered on Health Net Medicare Part D formularies.

Cost-sharing for Medicare beneficiaries follows a different structure than commercial plans. During the initial coverage phase, a member might pay a copay of $42 to $100 for a Tier 3 or Tier 4 brand drug. Once total drug spending reaches the coverage gap threshold ($5,630 in 2025 per CMS guidance), the manufacturer discount program and plan contributions reduce the member's share to 25% of the negotiated price 4. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, which took effect in 2025, has significantly reduced catastrophic-phase exposure for Medicare enrollees taking high-cost medications like Eliquis 5.

Low-income subsidy (LIS) recipients on Health Net Medicare plans may pay as little as $0 to $11.20 per prescription depending on their subsidy level. Members unsure of their LIS status can check eligibility through their local Social Security Administration office or the Medicare website.

Prior Authorization and Step Therapy Requirements

Health Net may require prior authorization for Eliquis under specific circumstances. For the two FDA-approved indications that account for the majority of prescriptions (stroke prevention in nonvalvular atrial fibrillation and treatment of deep vein thrombosis or pulmonary embolism), most Health Net plans approve Eliquis without prior authorization 6. The prescriber writes the script, and the pharmacy processes it against the formulary.

Step therapy is a different barrier. Some Health Net commercial plans require that a patient try warfarin first before the plan will approve a DOAC like Eliquis. This practice has drawn criticism from cardiology societies. The American College of Cardiology's 2019 focused update on atrial fibrillation management recommends DOACs over warfarin for most patients with nonvalvular AF, citing lower rates of intracranial hemorrhage and comparable or superior stroke prevention 7. If a Health Net plan imposes step therapy requiring warfarin first, the prescriber can file an exception request supported by clinical rationale.

Quantity limits also apply. Health Net typically allows 60 tablets per 30-day supply, consistent with the standard dosing of 5 mg twice daily for most indications. For the 2.5 mg twice-daily dose used in patients meeting at least two of three criteria (age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or greater), the quantity limit remains the same at 60 tablets 8.

What Eliquis Costs on Health Net Plans (Real-World Estimates)

Out-of-pocket costs vary widely across Health Net plan types. Here is a practical breakdown.

For commercial HMO and PPO plans, Tier 3 copays range from $40 to $75 per 30-day fill, and Tier 4 copays can reach $80 to $120. Plans with coinsurance instead of flat copays may charge 25% to 50% of the negotiated drug price, which for a brand-name DOAC can translate to $150 or more before any manufacturer copay assistance.

For Health Net Medicare Advantage (Part D) plans, initial coverage phase copays typically fall between $42 and $100. After reaching the $2,000 out-of-pocket maximum under the Inflation Reduction Act cap, the member pays $0 for the remainder of the plan year.

For Medi-Cal managed care through Health Net, Eliquis is generally available with a nominal copay of $1 to $3.80, as California's Medi-Cal program covers most FDA-approved anticoagulants.

Bristol-Myers Squibb and Pfizer offer a manufacturer co-pay savings card that can reduce out-of-pocket costs to as low as $10 per month for eligible patients with commercial insurance. This card does not apply to government-funded programs including Medicare, Medicaid, Tricare, or VA benefits 9.

The ARISTOPHANES study (N=321,182), a real-world retrospective analysis comparing DOACs, found that apixaban was associated with lower rates of major bleeding compared to rivaroxaban (HR 0.60, 95% CI 0.54 to 0.65) and dabigatran (HR 0.59, 95% CI 0.52 to 0.66), which may factor into formulary preference decisions by insurers 10.

How to Check Your Specific Health Net Plan's Eliquis Coverage

The fastest way to confirm coverage is to use Health Net's online formulary search tool. Log in to the member portal, manage to the pharmacy or prescription drug section, and search for "apixaban" or "Eliquis." The tool will display the tier, any prior authorization flags, quantity limits, and step therapy requirements.

If the online tool is unavailable, call Health Net's pharmacy benefit number listed on your member ID card. Have the following information ready: your member ID, the drug name and dose (e.g., apixaban 5 mg), the prescribing physician's NPI number, and the diagnosis code (ICD-10 I48.91 for unspecified atrial fibrillation, or I82.40 for acute DVT of unspecified deep vessels of lower extremity).

Pharmacists can also run a real-time benefit check (RTBC) at the point of sale. This electronic query returns the patient's exact copay, tier, and any coverage restrictions before the prescription is filled. The CMS mandate for RTBC integration in Medicare Part D plans has made this process standard at most chain pharmacies 11.

What to Do If Health Net Denies Coverage for Eliquis

A denial is not the end of the road. Health Net members have the right to appeal formulary exclusions or tier placement through several channels.

Internal exception request. The prescribing physician submits a coverage determination request explaining why Eliquis is medically necessary over formulary alternatives. Common clinical reasons include warfarin intolerance, labile INR despite adherence, history of warfarin-related bleeding, renal function considerations favoring apixaban's dual elimination pathway, or drug interactions precluding other DOACs. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66 to 0.95, P=0.01) and reduced major bleeding by 31% (HR 0.69, 95% CI 0.60 to 0.80, P<0.001) 12. These data strengthen exception requests.

External review. If the internal appeal is denied, members can request an independent external review. California's Department of Managed Health Care (DMHC) oversees this process for Health Net HMO members. PPO members may go through the California Department of Insurance.

Expedited review. If the patient faces an urgent clinical situation (active DVT/PE, new AF diagnosis with high CHA2DS2-VASc score), the prescriber can request an expedited decision, which Health Net must render within 24 hours for Medicare plans and 72 hours for commercial plans.

Dr. Gregory Lip, a professor of cardiovascular medicine at the University of Liverpool and developer of the CHA2DS2-VASc scoring system, has stated: "The evidence clearly favors direct oral anticoagulants over warfarin for stroke prevention in atrial fibrillation, and insurance coverage policies should reflect this clinical reality" 13.

Alternatives to Eliquis on Health Net Formularies

If cost remains prohibitive even after exception requests and copay cards, Health Net formularies include other anticoagulant options.

Warfarin (generic). Sits on Tier 1 across virtually all Health Net plans, costing $4 to $10 per month. Requires regular INR monitoring, dietary consistency regarding vitamin K intake, and carries higher intracranial hemorrhage risk. The RE-LY trial (N=18,113) and subsequent meta-analyses confirmed that DOACs as a class reduce intracranial bleeding by approximately 50% compared to warfarin 14.

Rivaroxaban (Xarelto). Often on the same tier as Eliquis (Tier 3 or 4) but may be a preferred brand on certain Health Net plans, resulting in a lower copay. Rivaroxaban has once-daily dosing for AF (20 mg with dinner), which some patients prefer over twice-daily apixaban. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention 15.

Dabigatran (Pradaxa). Another DOAC option that may appear on Health Net formularies. It has a specific reversal agent (idarucizumab), as does andexanet alfa for apixaban and rivaroxaban. Dabigatran is renally eliminated and less suitable for patients with creatinine clearance below 30 mL/min.

Edoxaban (Savaysa). Less commonly prescribed but FDA-approved for AF and VTE. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated noninferiority to warfarin with lower bleeding rates 16.

The 2023 ACC/AHA/ACCP/HRS guideline for management of patients with atrial fibrillation gives a Class I recommendation for DOACs over warfarin in eligible patients with AF, reinforcing that any formulary restriction requiring a warfarin trial first runs counter to current evidence-based practice 17.

Special Populations and Coverage Considerations

Certain patient groups face unique coverage dynamics on Health Net plans.

Patients with renal impairment. Apixaban's pharmacokinetic profile includes hepatic metabolism and renal excretion (approximately 27%), making it the preferred DOAC for patients with moderate-to-severe chronic kidney disease. The 2.5 mg twice-daily dose reduction criteria apply when two of three factors are present: age 80+, weight 60 kg or less, creatinine 1.5 mg/dL or higher. Health Net may approve Eliquis more readily via exception for CKD patients because rivaroxaban and dabigatran carry more renal clearance dependency 18.

Post-surgical VTE prophylaxis. For hip or knee replacement, Eliquis is FDA-approved at 2.5 mg twice daily for 12 days (knee) or 35 days (hip). Health Net may require documentation of the surgical procedure date and planned duration. Short-course prescriptions (10 to 35 days) typically encounter fewer coverage barriers than chronic-use prescriptions.

Cancer-associated thrombosis. The Caravaggio trial (N=1,170) demonstrated that apixaban was noninferior to dalteparin for recurrent VTE in cancer patients, with lower rates of major bleeding 19. Health Net may classify this as an off-label indication for AF-approved DOACs, potentially triggering prior authorization. The prescriber should cite Caravaggio and NCCN guidelines supporting DOAC use in cancer-associated VTE.

Dr. Manesh Patel, chief of the Division of Cardiology at Duke University Medical Center, has noted: "Apixaban's safety profile in patients with renal impairment and cancer-associated thrombosis gives it a distinct clinical advantage that should inform formulary decisions" 20.

The Manufacturer Copay Card and Patient Assistance Programs

Bristol-Myers Squibb's Eliquis 360 Support program offers two distinct pathways for reducing costs.

The co-pay savings card is available to commercially insured patients (not Medicare, Medicaid, or other government programs). Eligible patients can pay as little as $10 per 30-day supply, with the card covering up to a specified annual maximum. The card must be activated before use at the pharmacy and is presented alongside the insurance card at the point of sale.

The free drug program provides Eliquis at no cost to uninsured or underinsured patients who meet income eligibility criteria, typically household income at or below 300% of the federal poverty level. Application requires documentation of income and insurance status.

For Medicare patients who fall into coverage gaps, several nonprofit organizations offer copay assistance. The Patient Access Network (PAN) Foundation and the HealthWell Foundation periodically open funds for anticoagulant assistance, though these funds open and close based on donation cycles. Checking fund availability monthly is advisable for patients anticipating high out-of-pocket costs.

Pharmacists should counsel Health Net members that applying both the manufacturer card and insurance benefits is standard practice for commercial plans, but stacking assistance from multiple sources may violate program terms for government-insured patients under the federal Anti-Kickback Statute 21.